Alphabet’s supersecretive Calico Labs is losing its top artificial intelligence researcher as Chief Computing Officer Daphne Koller moves on to greener pastures.
“I have decided to leave Calico to pursue other professional opportunities,” Koller said in an emailed statement to Bloomberg. “I very much enjoyed my time at Calico, and have the greatest respect for the Calico team and their important and aspirational mission.”
Koller signed on with Calico in August 2016 to lead its machine learning and computational biology team. Her job? To build a team that can analyze large volumes of health data and change the way we think about aging and disease.
She joined the company from Coursera, the education tech outfit she founded in 2012.
In addition to applying existing machine learning techniques to biological data, she also intended to develop new kinds of machine learning that can change human health, she told FierceBiotech in September that year.
And her path at Calico was uncharted—because her approach was data-driven, the specific indications Calico would tackle hinged on which data are produced and what her team learned from analyzing it.
“Daphne has been instrumental in helping to build our machine learning and computing infrastructure and has made many important contributions as we aim to bring the vast capabilities of machine learning to bear on advancing our understanding of the biological mechanisms by which we age,” Calico spokesman Neil Cohen said, according to Bloomberg.
Koller’s departure is Calico’s second high-profile exit in recent months. In November, its R&D chief, Hal Barron, jumped ship to take the chief scientific officer position at GlaxoSmithKline.
The Big Pharma hired Barron, who now heads a new GSK office in San Francisco, to shake up R&D as it has seen few approvals or exciting research updates in the last few years.
By Amirah Al Idrus
Source: Fierce Biotech
Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer seeks a successor for its blockbuster drug.
The Food and Drug Administration on Tuesday cleared a new kind of oral antibiotic for the treatment of common urinary tract infection in women and girls 12 years or older. The oral drug gepotidacin, which its maker GSK will sell as Blujepa, is approved to treat uncomplicated urinary tract infections caused by five common types of bacteria, including E. coli.
23andMe, the DNA testing company once valued at $6 billion, filed for Chapter 11 bankruptcy protection on Sunday as it runs low on cash. CEO and co-founder Anne Wojcicki resigned on Sunday but will remain a director on the board. Joseph Selsavage, 23andMe’s chief financial and accounting officer, was named interim CEO.
